ESMO 2024 Spotlight: Matchmell Study

GI Cancer ESMO 2024 Highlights: Key Studies Discussed LEAP-012, KEYNOTE-811, POD1UM-303, NICHE-2Подробнее

Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12Подробнее

MEDSIR inside ESMO 2024 - Highlights Day 3Подробнее

Colorectal cancer highlights at ESMO 2024: CheckMate 8HW and BREAKWATERПодробнее

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATICПодробнее

POCHI: pembrolizumab, CAPOX and bevacizumab in pMMR/MSS CRC at ESMO 2024Подробнее

ESMO 2024 Spotlight: The CITUCEL Trial UpdateПодробнее

What to look forward to in GU cancers at ESMO 2024Подробнее

Video shots | Highlights and latest updates from ESMO 2024Подробнее

Divergent outcomes in pancreatic cancer trials at ESMO GI 2024Подробнее

ESMO 2024: Highlights and analysisПодробнее

Highlights in breast cancer at ESMO 2024: KEYNOTE-522Подробнее

ESMO 2024 – Dr Meredith McKeanПодробнее

Bladder cancer at ESMO 2024: SunRISe-4, TOMBOLA and NIAGARAПодробнее

PEACE-3 Study ESMO 2024 - Combining Enzalutamide + Radium-223 in mCRPCПодробнее

Ovarian cancer at ESMO 2024: PRIMA and ATHENAПодробнее

ESMO 2024 Key Highlights in Liver Cancer: LEAP-012 and IMbrave050 DiscussionПодробнее